McKesson Corporation raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution businesses.

By Mrinalika Roy and Mariam Sunny Feb 4 (Reuters) - Eli Lilly forecast strong profit growth for 2026 on Wednesday on the back ...

Driven by breakthroughs in filter media and innovative technologies for injectables, vaccines, APIs, and advanced therapies, ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

GSK reports a net profit of £5.7 billion, a sharp rise driven by strong sales in HIV, respiratory, and cancer drugs, ...

Eton Pharmaceuticals, Inc. is rated Buy with revenue growth, FCF positivity & declining SG&A margins support. Learn more ...

WENZHOU, ZHEJIANG PROVINCE, CHINA, January 19, 2026 /EINPresswire.com/ -- As the global pharmaceutical and healthcare ...

Nirmala Sitharaman’s Biopharma SHAKTI announcement in the Union Budget has worked as a booster for the biotechnology sector ...

Q1 2026 earnings call recap: raised FY26 guidance, OneOncology integration, EPS/revenue highlights, risks and outlook—read ...

Vertex Pharmaceuticals' late-stage pipeline. Vertex Pharmaceuticals' strategy is to develop medicines in areas with high ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the stocks that Jim Cramer shared takes on, along with ...

There's a growth stock that has skyrocketed more than Google parent Alphabet ( GOOG 0.04%) ( GOOGL 0.07%) and Nvidia ( NVDA 0 ...